Skip to main content
CNTX
NASDAQ Life Sciences

CTIM-76获得FDA快速审批资格，用于治疗铂类药物抵抗的卵巢癌

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
8
Price
$2.72
Mkt Cap
$243.48M
52W Low
$0.49
52W High
$3.62
Market data snapshot near publication time

summarizeSummary

Context Therapeutics宣布，其药物候选物CTIM-76已获得FDA快速审批资格，用于治疗铂类药物抵抗的卵巢癌。这一资格是一个重要的正面监管里程碑，因为它旨在加快解决严重情况和未满足的医疗需求的药物的开发和审查，可能会加速CTIM-76上市的进程。这一消息建立在2026年3月23日公司报告的CTIM-76 1a期试验中确认的部分反应的积极势头上。投资者现在将关注CTIM-76项目的中期数据，预计将在2026年6月公布。

在该公告发布时，CNTX的交易价格为$2.72，交易所为NASDAQ，所属行业为Life Sciences，市值约为$2.4亿。 52周交易区间为$0.49至$3.62。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed CNTX - Latest Insights

CNTX
Apr 28, 2026, 4:12 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Shareholders to Vote on 100 Million Share Increase, Enabling Over 100% Potential Dilution
Sentiment: Negative
View Wiseek Article
CNTX
Apr 17, 2026, 4:29 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Context Therapeutics Seeks Shareholder Approval to Double Authorized Common Stock
Sentiment: Negative
View Wiseek Article
CNTX
Apr 02, 2026, 7:41 AM EDT
Filing Type: 8-K
Importance Score:
8
Context Therapeutics' CTIM-76 Receives FDA Fast Track Designation for Platinum-Resistant Ovarian Cancer
Sentiment: Positive
View Wiseek Article
CNTX
Apr 02, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
CTIM-76 Receives FDA Fast Track Designation for Platinum-Resistant Ovarian Cancer
Sentiment: Positive
View Wiseek Article
CNTX
Mar 23, 2026, 4:23 PM EDT
Source: Wiseek News
Importance Score:
8
Partial Response Reported for Context's CTIM-76, Key Milestones Ahead; Cash Runway into Mid-2027
Sentiment: Positive
View Wiseek Article
CNTX
Mar 23, 2026, 4:22 PM EDT
Filing Type: 8-K
Importance Score:
8
Context Therapeutics Reports Partial Response in CTIM-76 Phase 1a Trial, Extends Cash Runway
Sentiment: Positive
View Wiseek Article
CNTX
Mar 23, 2026, 4:09 PM EDT
Filing Type: 10-K
Importance Score:
8
Context Therapeutics Reports Increased Losses, $75M ATM Program, and Over 100% Potential Dilution
Sentiment: Negative
View Wiseek Article
CNTX
Mar 13, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
8
Court Approves Governance Changes, Eliminating Staggered Board and 'For Cause' Director Removal
Sentiment: Positive
View Wiseek Article
CNTX
Feb 27, 2026, 4:11 PM EST
Filing Type: 8-K
Importance Score:
8
Context Therapeutics to Adopt Annual Director Elections, Resolving Shareholder Lawsuit
Sentiment: Positive
View Wiseek Article
CNTX
Jan 08, 2026, 7:43 AM EST
Filing Type: 8-K
Importance Score:
8
Context Therapeutics Reports Positive Interim Phase 1a Data for CTIM-76 and Extends Cash Runway
Sentiment: Positive
View Wiseek Article